HIV-prevention advocacy group PrEP4All Collaboration filed a petition with the U.S. Patent and Trademark Office alleging that Gilead Sciences intentionally delayed the development of a safer drug for human immunodeficiency virus.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2019-12-06 13:01:532019-12-06 13:01:53Gilead Fends Off Monopoly Accusation from HIV Advocacy Group PrEP4All
